- Home
- MGNX vs FNGR Comparison
MGNX vs FNGR Comparison
Compare MGNX & FNGR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MGNX
- FNGR
- Stock Information
- Founded
- MGNX 2000
- FNGR 2016
- Country
- MGNX United States
- FNGR Singapore
- Employees
- MGNX N/A
- FNGR N/A
- Industry
- MGNX Biotechnology: Pharmaceutical Preparations
- FNGR Computer Software: Prepackaged Software
- Sector
- MGNX Health Care
- FNGR Technology
- Exchange
- MGNX Nasdaq
- FNGR Nasdaq
- Market Cap
- MGNX 70.3M
- FNGR 72.0M
- IPO Year
- MGNX 2013
- FNGR N/A
- Fundamental
- Price
- MGNX $1.43
- FNGR $3.50
- Analyst Decision
- MGNX Hold
- FNGR
- Analyst Count
- MGNX 10
- FNGR 0
- Target Price
- MGNX $6.83
- FNGR N/A
- AVG Volume (30 Days)
- MGNX 599.1K
- FNGR 830.3K
- Earning Date
- MGNX 05-20-2025
- FNGR 06-27-2025
- Dividend Yield
- MGNX N/A
- FNGR N/A
- EPS Growth
- MGNX N/A
- FNGR N/A
- EPS
- MGNX N/A
- FNGR N/A
- Revenue
- MGNX $149,962,000.00
- FNGR $33,570,107.00
- Revenue This Year
- MGNX N/A
- FNGR $260.03
- Revenue Next Year
- MGNX $80.86
- FNGR N/A
- P/E Ratio
- MGNX N/A
- FNGR N/A
- Revenue Growth
- MGNX 155.26
- FNGR N/A
- 52 Week Low
- MGNX $0.99
- FNGR $1.03
- 52 Week High
- MGNX $14.91
- FNGR $3.65
- Technical
- Relative Strength Index (RSI)
- MGNX 43.37
- FNGR 78.74
- Support Level
- MGNX $1.54
- FNGR $2.75
- Resistance Level
- MGNX $1.82
- FNGR $3.52
- Average True Range (ATR)
- MGNX 0.15
- FNGR 0.33
- MACD
- MGNX 0.01
- FNGR 0.16
- Stochastic Oscillator
- MGNX 19.79
- FNGR 99.06
About MGNX MacroGenics Inc.
Macrogenics Inc is a biotechnology company focused on discovering and developing antibody-based therapeutics for the treatment of cancer. Its product includes MARGENZA, which is for the treatment of adult patients with metastatic HER2-positive breast cancer. It's a pipeline of product candidates designed to target either various tumor-associated antigens or immune checkpoint molecules. The company has three proprietary product candidates in clinical development: lorigerlimab, a bispecific DART molecule that targets checkpoint inhibitors PD-1 and CTLA-4; MGC026, an ADC that targets B7-H3 and delivers a novel topoisomerase I inhibitor (TOP1i)-based linker-payload, and MGC028, an ADC that targets ADAM9 and delivers a novel TOP1i-based linker-payload.
About FNGR FingerMotion Inc.
FingerMotion Inc is engaged in the provision of mobile payment and recharge services in the Chinese market. The company business line includes Telecommunications Products and Services; Value Added Products and Services; Short Message Services (SMS) and Multimedia Messaging Services (MMS); a Rich Communication Services (RCS) platform; Big Data Insights; and a Video Games Division (inactive). It principally earns revenue by providing mobile payment and recharge services to customers of telecommunications companies in China.